Grifols has been included in the FTSE4Good Index

Barcelona, July 16, 2018.- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company that enhances the health and well-being of patients through the development of plasma-derived medicines, clinical diagnostic solutions and specialty pharmaceuticals for hospital use, has been included in sustainability stock index FTSE4Good.

The sustainability indices consider environmental, social and governance (ESG) criteria in addition to financial indicators.

Specifically, Grifols has been chosen to form part of the FTSE4Good Global, FTSE4Good Europe and FTSE4Good Ibex indices.

The FTSE4Good Index independently rates companies on their environmental, social and corporate governance (ESG) performance. The FTSE4Good indices are used by a broad range of financial market agents in their investment decisions.

The benchmarks for inclusion in FTSE4Good are based on an extensive market consultation process that encompasses numerous stakeholder groups, including government entities, consultants, academics, investment experts, the business community and NGOs.